Anteotech Ltd · ASX:ADO
Anteotech — Anteo Diagnostics — Shareholder Meeting (November 2009)
27 slides from Anteotech's shareholder meeting presentation, Nov 23, 2009
Slide 1: Annual General Meeting 23rd November 2009
For personal use only ANTEO DIAGNOSTICS LTD (ASX:ADO) Annual General Meeting 23rd November 2009 WELCOME
Slide 2: Meeting Format
MEETING FORMAT For personal use only • Introductions • Chairman’s Review • Financial Accounts • Formal Resolutions • Other Business • Meeting Close • CEO Report
Slide 3: Introductions
For personal use only INTRODUCTIONS
Slide 4: Introductions
INTRODUCTIONS For personal use only Anteo Diagnostics Limited Richard Martin – Non Executive Director - Meeting Chairman Dr Geoff Cumming – CEO Lara Iacusso – Non Executive Director Dr Robert Gilmour – Non Executive Director Joe Maeji – Chief Scientific Officer Nevin Abernethy – Chief Product Develo
Slide 5: Chairman's Review
For personal use only CHAIRMAN’S REVIEW
Slide 6: 2009 Year in Review
2009,YEAR IN REVIEW For personal use only This year the company has focused on consolidating its core strengths, understanding its potential markets and moving towards the commercialisation of the company’s Mix&Go technology. In particular the company has achieved the following: •Appointed a new CEO
Slide 7: 2009 Year in Review
2009,YEAR IN REVIEW For personal use only Result for the Year to 30 June 2009 The net consolidated operating loss $1.95 million and represented the ongoing effort directed towards developing and commercializing the Mix&Go products Changes to the Board of Directors In December, James Henderson was ap
Slide 8: Financial Accounts
For personal use only FINANCIAL ACCOUNTS
Slide 9: Profit and Loss
PROFIT AND LOSS For personal use only Economic Entity Parent Entity 2009 2008 2009 2008 Note $ $ $ $ Sales revenue 2 226,312 81,114 - - Cost of sales - - - - Gross profit 226,312 81,114 - - Other revenue from ordinary activities 2 575,607 1,140,515 120,560 64,808 Selling and distribution expenses (3
Slide 10: Balance Sheet
BALANCE SHEET For personal use only Economic Entity Parent Entity 2009 2008 2009 2008 Note $ $ $ $ CURRENT ASSETS Cash assets 8 953,354 3,120,952 931,338 3,099,834 Receivables 9 75,643 137,830 4,088 2,654 Other 10 1,541 1,387 1,541 1,387 TOTAL CURRENT ASSETS 1,030,538 3,260,169 936,967 3,103,875 NON
Slide 11: Cash Flow
CASH FLOW For personal use only Economic Entity Parent Entity Note 2009 2008 2009 2008 $ $ $ $ Cash Flows from Operating Activities: Receipts from customers and government 734,141 1,131,446 - - grants Payments to suppliers and employees (2,796,997) (2,666,345) (704,425) (734,548) Borrowing costs (56
Slide 12: Formal Resolutions
For personal use only FORMAL RESOLUTIONS
Slide 13: Resolutions
RESOLUTIONS For personal use only Resolution 1 – Adoption of Director’s Remuneration Report Resolution 2 – Re-Election of Director, Mr Richard Martin Resolution 3 – Re -Election of Director, Dr Geoffrey Cumming Resolution 4 – Re -Election of Director, Mr James Henderson Resolution 5 – Issue of Optio
Slide 14: Resolutions
RESOLUTIONS For personal use only Resolution For Against Open Abstain 1 Adoption of 73,953,907 43,870 1,499,773 24,000 Remuneration Report 2 Re-election of Mr 75,206,577 12,200 302,773 - Richard Martin as a Director 3 Re-election of Dr 73,982,925 38,852 1,499,773 - Geoffrey Cumming as a Director 4 R
Slide 15: Other Business and Question Time
For personal use only OTHER BUSINESS AND QUESTION TIME
Slide 16: CEO Address - 2009 AGM
For personal use only ANTEO DIAGNOSTICS LTD (ASX:ADO) Better Diagnostics - Faster CEO ADDRESS – 2009 AGM 23rd November 2009
Slide 17: Current Status
Current Status For personal use only • ADO initial product, Mix&GoTM , has numerous competitive advantages over current practices • Mix&GoTM ready for sale – no further development work required • Mix&GoTM markets include Pathology Suppliers, Bead Manufacturers and Research Organisations – globally
Slide 18: Current Status
Current Status For personal use only • ADO is engaged in discussions or negotiations with major market participants across all segments • Highly skilled team and facilities in place
Slide 19: Mix&Go Technology
Mix&GoTM Technology For personal use only In immunoassays (a dominant test in pathology), Signal Proteins (used to detect disease markers) are bound to synthetic surfaces. Depending on the surface, proteins are damaged leading to decreased performance. Mix&GoTM has been developed to capture and orie
Slide 20: Mix&Go Markets
Mix&GoTM Markets For personal use only Mix&GoTM Pathology Bead Research Point of Suppliers Manufacturers Organisations Care Pathology Laboratories Buys Mix&GoTM ADO coats beads Point of care from ADO, coat with Mix&GoTM testing devices Buys Mix&GoTM own products and and sells to incorporate from ADO
Slide 21: Mix&Go Markets - Pathology Suppliers
Mix&GoTM Markets – Pathology Suppliers For personal use only • Addressable market size ~ $6 B in laboratory based immunoassay tests per annum • Major participants – Roche, Siemens, Abbott, Ortho, Beckman, BD, bioMerieux, DiaSorin • Interest in Mix&GoTM from pathology suppliers for: – high volume tes
Slide 22: Mix&Go Markets - Bead Manufacturers
Mix&GoTM Markets – Bead Manufacturers For personal use only • Supply Pathology Suppliers and Research Organisations • Major bead suppliers to pathology market – Merck, Dynal, Seradyn, Bangs • Interest in Mix&GoTM from bead manufacturers as: – easier to produce – less variability – greater stability
Slide 23: Mix&Go Markets - Research Organisations
Mix&GoTM Markets – Research Organisations For personal use only • No regulatory barriers • Major bead suppliers to research organisations - Dynal, Seradyn, Bangs, Ademtech, Miltenyi, Luminex, Chemagen • More “user friendly” product • Generally willing to pay higher prices, but lower volumes
Slide 24: Mix&Go Markets - Point of Care
Mix&GoTM Markets – Point of Care For personal use only • Variety of tests including: – Strep B – Urinary tract infections, – TB – Cardiac monitoring – Blood coagulation – LDL cholesterol • Major suppliers Pall Corporation, Whatman (GE), Millipore • High volume products • Total market > $5B per annum
Slide 25: Mix&Go Markets - Business Models
Mix&GoTM Markets – Business Models For personal use only PATHOLOGY BEAD RESEARCH POINT OF SUPPLIERS MANUFACTURERS ORGANISATIONS CARE Upfront payment Upfront payment Supply of Mix&Go Upfront Supply of Supply of Mix&Go for research and payment Mix&Go for reagent collaboration Research and feasibility
Slide 26: Mix&Go Market Engagement
Mix&GoTM Market Engagement For personal use only Market Signed MTA Signed NDA Pathology Suppliers 4 6 of top 10 Bead Manufacturers All major bead manufactures Research Organisations Accessed through Accessed through other segments other segments Point of care 2 of 3 major suppliers MTA = Materials T
Slide 27: Other Mix&Go Applications
Other Mix&GoTM Applications For personal use only • Other (non-human) diagnostic markets – including veterinary and agriculture • Other diagnostic platforms – including biosensors and biochips • In Bioseparations – for example, antibody and streptavidin beads are used in research and in purification
Anteo Diagnostics — Shareholder Meeting (November 2009) on 6ix